Ashleigh Furlong is a health care reporter at Bloomberg. She specializes in medicine and healthcare, covering topics such as public health, pharmaceuticals, and healthcare technology, with a keen focus on the intersection of health and finance. Ashleigh's work has been featured in prominent outlets including Yahoo Finance, Scientific American, and TIME.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Ashleigh Furlong's coverage spans a variety of topics, with a significant focus on healthcare and pharmaceutical issues. She places particular emphasis on government announcements, legal policy regulation, and breaking news.
Given her extensive coverage of healthcare and pharmaceutical matters, she may be interested in receiving pitches related to these areas. For instance, providing insights into recent health crises or developments in drug policies could resonate well with her area of expertise.
It is important to note that Ashleigh also covers international relations and conflicts such as the Middle East conflict and Russia-Ukraine conflict. Therefore, if your pitch relates to any evolving stories within these areas or includes relevant data citations from reputable sources, it might catch her attention.
Additionally, considering Ashleigh's frequent reference to government announcements and legal policy regulations in her coverage attributes suggests that she would likely appreciate pitches offering analysis or expert commentary on new legislative measures impacting the sectors she covers.
This information evolves through artificial intelligence and human feedback. Improve this profile .
AstraZeneca Plc’s profit grew more than expected in the first quarter, bolstered by demand for its blockbuster cancer medicines.
By: Naomi Kresge, Ashleigh Furlong
GSK Plc’s profit was higher than analysts expected in the first quarter, helped by the drugmaker’s specialty medicines for HIV, cancer and immune diseases.
(Bloomberg) -- GSK Plc's older respiratory medicines showed lackluster sales in the first quarter, leaving HIV and cancer drugs to drive profit growth.
AstraZeneca Plc will invest £300 million ($405 million) in UK life sciences, Prime Minister Keir Starmer told Parliament, a deal he said was enabled by the trade deal between Britain and the US.
By: Jessica Nix, Ashleigh Furlong
AstraZeneca Plc failed to persuade a US regulatory review panel about the benefits of its novel breast cancer medicine, throwing a hurdle in front of a key drug in the company’s pipeline.
By: Ashleigh Furlong
AstraZeneca Plc’s new hypertension pill won US Food and Drug Administration approval in a boost for the drugmaker that’s seeking to garner more than $5 billion in annual sales from the medicine.
(Bloomberg) -- AstraZeneca Plc's new hypertension pill won US Food and Drug Administration approval in a boost for the drugmaker that's seeking to
By: Janice Kew, Ashleigh Furlong
Production of an experimental Ebola vaccine from the developers of a Covid-19 shot is expected to begin soon, with animal studies underway as researchers race to bring a much-needed tool to the spiraling outbreak.
GSK Plc’s experimental hepatitis B drug eliminated all signs of the disease in about one-in-five patients, a new study showed, in a boost for the medicine the company expects to become a blockbuster.
By: Jason Gale, Ashleigh Furlong, Naomi Kresge
Los desarrolladores y financiadores de vacunas avanzan con tres vacunas experimentales contra la cepa del ébola que se propaga rápidamente en África Central.
